knowledge -WSS

knowledge

author：knowledge 2025-09-06 06:54:35 Page View：22

Erik Tokat -- biotech JPM coverage from STAT — Eric Tokat is co-president of investment banking at Centerview Partners. Courtesy Centerview Partners

SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong year for acquisitions, driven by Big Pharma’s need to restock pipelines with medicines that can generate sales in the coming years.

That’s not idle speculation. It’s perhaps as close to a guarantee one can get in biotech. Last year, Tokat’s advisory firm, Centerview Partners, was involved in 19 of the 23 biotech transactions valued at $1 billion or more. Two more acquisitions of Centerview clients — Harpoon Therapeutics and Ambrx Biopharma — were announced Monday morning.

“I’m not sure if we’re going to have 23 deals or 25 deals, but I think it’s going to be a good year,” said Tokat, speaking to STAT over coffee on the sidelines of the J.P. Morgan Healthcare Conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Donor acceptance rates hint at racial, gender bias in heart transplants: study
Next article： Wildfire smoke exposes gaps in outdoor worker protections

explore

Continuity nursing helped my family in our darkest PICU moments

EssayauthorSarahMcCarthycuddleswithherdaughterMolly.CourtesySarahMcCarthyTheventilatoralarmwokemeat3

Readout LOUD podcast: mifepristone case, GLP

WhogetstosuetheFDA?Ispharmacaughtinatradewar?Andwhatdoes“AF”standfor?Wecoverallthatandmorethisweekon

After affirmative action ruling, medical educators look to 'holistic review'

AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

H.R. 3 is the wrong path to lower drug costs

Fromleft,Rep.RichardNeal(D-Mass.)speaksasRep.FrankPallone(D-N.J.)andHouseSpeakerNancyPelosi(D-Calif.

knowledge

leisure time

explore

H.R. 3 is the wrong path to lower drug costs